These findings provided important evidence that miR‐148b could suppress glycolysis in gastric cancer through directly targeting SLC2A1, further suggesting miR‐148b may be a potential biomarker and therapeutic target in gastric cancer treatment. The gene discussed is SLC2A1; the disease is gastric cancer.